- Home
- NGL vs IGMS Comparison
NGL vs IGMS Comparison
Compare NGL & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGL
- IGMS
- Stock Information
- Founded
- NGL 1940
- IGMS 1993
- Country
- NGL United States
- IGMS United States
- Employees
- NGL N/A
- IGMS N/A
- Industry
- NGL Natural Gas Distribution
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- NGL Utilities
- IGMS Health Care
- Exchange
- NGL Nasdaq
- IGMS Nasdaq
- Market Cap
- NGL 564.5M
- IGMS 528.6M
- IPO Year
- NGL 2011
- IGMS 2019
- Fundamental
- Price
- NGL $4.75
- IGMS $6.90
- Analyst Decision
- NGL
- IGMS Buy
- Analyst Count
- NGL 0
- IGMS 7
- Target Price
- NGL N/A
- IGMS $17.43
- AVG Volume (30 Days)
- NGL 260.0K
- IGMS 219.5K
- Earning Date
- NGL 02-06-2025
- IGMS 11-08-2024
- Dividend Yield
- NGL N/A
- IGMS N/A
- EPS Growth
- NGL N/A
- IGMS N/A
- EPS
- NGL N/A
- IGMS N/A
- Revenue
- NGL $6,239,231,000.00
- IGMS $2,918,000.00
- Revenue This Year
- NGL N/A
- IGMS $386.95
- Revenue Next Year
- NGL $2.34
- IGMS N/A
- P/E Ratio
- NGL N/A
- IGMS N/A
- Revenue Growth
- NGL N/A
- IGMS 57.64
- 52 Week Low
- NGL $3.84
- IGMS $6.17
- 52 Week High
- NGL $6.20
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- NGL 58.20
- IGMS 29.48
- Support Level
- NGL $4.57
- IGMS $7.00
- Resistance Level
- NGL $4.93
- IGMS $10.80
- Average True Range (ATR)
- NGL 0.18
- IGMS 0.94
- MACD
- NGL -0.00
- IGMS -0.10
- Stochastic Oscillator
- NGL 57.14
- IGMS 2.98
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, and for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.